Hypertension is Common in Patients with Newly Diagnosed Acromegaly and is Independently Associated with Renal Resistive Index

  • Hilmi Erdem Sumbul
  • Ayse Selcan KocEmail author
Original Article



There are conflicting results regarding the frequency of hypertension (HT) and values of related parameters in patients with acromegaly.


We aimed to determine the frequency of HT and values of its associated parameters in patients with acromegaly.


57 patients with newly diagnosed acromegaly were included in this study. Renal ultrasonography (US) was performed in addition to routine evaluation of acromegaly. Renal resistive index (RRI), renal pulsatility index (RPI), and accelerated time were measured using Doppler US.


Hypertension was detected in 16 patients (28.1%) with newly diagnosed acromegaly. Serum triglyceride, TSH, growth hormone, and insulin growth factor 1 levels were higher and HDL levels were lower in acromegaly patients with HT. RRI and RPI values were found to be higher in acromegaly patients with HT. In logistic regression analysis, only the RRI value was found to be independently related to the presence of HT. Based on this analysis, it was determined that the frequency of HT increases 2.99 times for each increase in RRI of 0.05 units. When ROC analysis was performed, it was found that the area under the ROC curve was 0.781. In the same analysis, when the cutoff value for RRI was taken to be 0.70, the development of HT in acromegaly patients was determined with 75% sensitivity and 78% specificity.


In patients with newly diagnosed acromegaly, HT frequency was significantly increased and it was independently associated with the RRI value. Therefore, these patients should be closely monitored for HT—the most frequent and important cardiovascular risk factor—and treated before they develop target organ damage.


Acromegaly Hypertension Renal resistive index Renal ultrasonography 


Compliance with Ethical Standards

Conflict of interest

There is no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–51.Google Scholar
  2. 2.
    Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CMG, Pinedo AC, Guerrero DP, Barrera CA, Franco HI, Ribeiro-Oliveira A Jr, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19:448–57.Google Scholar
  3. 3.
    Pivonello R, Auriemma RS, Grasso LFS, Pivonello C, Simeoli C, Patalano R, Galdiero M, Colao A. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20:46–62.Google Scholar
  4. 4.
    Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159–219.Google Scholar
  5. 5.
    Hansen TK, Møller J, Thomsen K, Frandsen E, Dall R, Jørgensen JO, Christiansen JS. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab. 2001;281:E1326–32.Google Scholar
  6. 6.
    Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev. 1996;17:423–80.Google Scholar
  7. 7.
    Møller J, Jørgensen JO, Marqversen J, Frandsen E, Christiansen JS. Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor. Clin Endocrinol (Oxf). 2000;52:181–6.Google Scholar
  8. 8.
    Díez J. Insulin-like growth factor I in essential hypertension. Kidney Int. 1999;55:744–59.Google Scholar
  9. 9.
    Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension. 1997;29:691–9.Google Scholar
  10. 10.
    Mosca S, Paolillo S, Colao A, et al. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol. 2013;167:1712–8.Google Scholar
  11. 11.
    Kamenicky P, Mazziotti G, Lombes M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014;35:234–81.Google Scholar
  12. 12.
    Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf). 2005;63:470–6.Google Scholar
  13. 13.
    Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Italian Study Group of Acromegaly, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189–98.Google Scholar
  14. 14.
    Powlson AS, Gurnell M. Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology. 2016;103:75–85.Google Scholar
  15. 15.
    Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4:239–49.Google Scholar
  16. 16.
    Berni A, Ciani E, Bernetti M, Cecioni I, Berardino S, Poggesi L, Abbate R, Boddi M. Renal resistive index and low-grade inflammation in patients with essential hypertension. J Hum Hypertens. 2012;26:723–30.Google Scholar
  17. 17.
    Boddi M, Cecioni I, Poggesi L, Fiorentino F, Olianti K, Berardino S, La Cava G, Gensini G. Renal resistive index early detects chronic tubulointerstitial nephropathy in normo- and hypertensive patients. Am J Nephrol. 2006;26:16–21.Google Scholar
  18. 18.
    Doi Y, Iwashima Y, Yoshihara F, Kamide K, Takata H, Fujii T, Kubota Y, Nakamura S, Horio T, Kawano Y. Association of renal resistive index with target organ damage in essential hypertension. Am J Hypertens. 2012;25:1292-8.Google Scholar
  19. 19.
    Tedesco MA, Natale F, Mocerino R, Tassinario G, Calabrò R. Renal resistive index and cardiovascular organ damage in a large population of hypertensive patients. J Hum Hypertens. 2007;21:291–6.Google Scholar
  20. 20.
    Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, Leoncini G, Ruello N, Zagami P, Bezante GP, et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant. 1999;14:360–5.Google Scholar
  21. 21.
    Yaron M, Izkhakov E, Sack J, Azzam I, Osher E, Tordjman K, Stern N, Greenman Y. Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors. Pituitary. 2016;19:322–31.Google Scholar

Copyright information

© Italian Society of Hypertension 2018

Authors and Affiliations

  1. 1.Department of Internal MedicineUniversity of Health Sciences—Adana Health Practice and Research CenterAdanaTurkey
  2. 2.Department of RadiologyUniversity of Health Sciences—Adana Health Practice and Research CenterAdanaTurkey

Personalised recommendations